PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis

Company Overview

PROCEPT BioRobotics is a medical technology company specializing in robotically enabled solutions for urological applications. The company’s flagship product, the AquaBeam® Robotic System, employs high-velocity waterjet technology to perform minimally invasive treatment of benign prostatic hyperplasia (BPH). Designed to enhance precision and consistency, AquaBeam offers a targeted approach that preserves healthy tissue while reducing procedure times and facilitating quicker patient recovery compared to traditional surgical methods.

In addition to its therapeutic platform, PROCEPT BioRobotics has developed the HERO® System, which integrates robotic assistance and advanced imaging for targeted prostate mapping and biopsy. By combining spatial localization with automated needle guidance, the HERO System aims to improve diagnostic accuracy for prostate cancer while minimizing patient discomfort and procedural variability. Together, these offerings reflect the company’s focus on leveraging robotics to address unmet needs in urology.

Founded in 2009 and headquartered in Redwood City, California, PROCEPT BioRobotics has expanded its footprint across North America, Europe and select international markets. The company holds multiple regulatory approvals, including FDA clearance and CE Mark certification, enabling its platforms to be adopted by leading hospitals and outpatient centers worldwide. PROCEPT continues to invest in clinical research, partnering with academic institutions to generate evidence on the safety, efficacy and cost-effectiveness of its technologies.

Under the leadership of President and CEO Elliot V. Bothell, PROCEPT BioRobotics has grown its commercial and clinical teams to support ongoing product innovation and market expansion. The management team includes seasoned professionals with backgrounds in medical devices, robotics and healthcare operations. As PROCEPT builds on its initial milestones, it remains committed to advancing patient care through precision robotics and data-driven solutions in urology.

Key Stats

• Today's Range: $55.82 to $59.25
• 50-Day Range: $53.04 to $65.05
• 52-Week Range: $47.04 to $103.81
• Volume: 660,432 shs
• Average Volume: 849,394 shs
• Market Capitalization: $3.14 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $84.13
• Consensus Rating: Moderate Buy

PROCEPT BioRobotics Stock Analysis - MarketRank™

PROCEPT BioRobotics scored higher than 50% of companies evaluated by MarketBeat, and ranked 633rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

PROCEPT BioRobotics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

PROCEPT BioRobotics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($1.75) to ($1.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PROCEPT BioRobotics is -33.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PROCEPT BioRobotics is -33.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PROCEPT BioRobotics has a P/B Ratio of 7.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.95% of the float of PROCEPT BioRobotics has been sold short.

Short Interest Ratio / Days to Cover

PROCEPT BioRobotics has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in PROCEPT BioRobotics has recently increased by 1.34%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PROCEPT BioRobotics does not currently pay a dividend.

Dividend Growth

PROCEPT BioRobotics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.95% of the float of PROCEPT BioRobotics has been sold short.

Short Interest Ratio / Days to Cover

PROCEPT BioRobotics has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in PROCEPT BioRobotics has recently increased by 1.34%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.34

News Sentiment

PROCEPT BioRobotics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for PROCEPT BioRobotics this week, compared to 7 articles on an average week.

Search Interest

Only 2 people have searched for PRCT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added PROCEPT BioRobotics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, PROCEPT BioRobotics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,271,250.00 in company stock.

Percentage Held by Insiders

17.40% of the stock of PROCEPT BioRobotics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

89.46% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PRCT Stock Analysis - Frequently Asked Questions

How have PRCT shares performed this year?

PROCEPT BioRobotics' stock was trading at $80.52 on January 1st, 2025. Since then, PRCT stock has decreased by 29.7% and is now trading at $56.6350.

How were PROCEPT BioRobotics' earnings last quarter?

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) announced its earnings results on Thursday, April, 24th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.04. The business's revenue for the quarter was up 55.5% on a year-over-year basis.
Read the conference call transcript.

When did PROCEPT BioRobotics IPO?

PROCEPT BioRobotics (PRCT) raised $126 million in an initial public offering on Wednesday, September 15th 2021. The company issued 5,500,000 shares at $22.00-$24.00 per share.

Who are PROCEPT BioRobotics' major shareholders?

Top institutional investors of PROCEPT BioRobotics include Harbor Capital Advisors Inc. (0.08%), Diversified Trust Co (0.02%) and Mirador Capital Partners LP (0.01%). Insiders that own company stock include Frederic H Moll, Reza Zadno, Morgan Colby Wood, Kevin Waters, Hisham Shiblaq, Alaleh Nouri and Antal Rohit Desai.
View institutional ownership trends.

How do I buy shares of PROCEPT BioRobotics?

Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PROCEPT BioRobotics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PROCEPT BioRobotics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), Netflix (NFLX), Tesla (TSLA), NVIDIA (NVDA), SPDR Dow Jones Industrial Average ETF Trust (DIA) and Meta Platforms (META).

Company Calendar

• Last Earnings: 4/24/2025
• Today: 7/16/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PRCT
• CIK: 1588978
• Web: www.procept-biorobotics.com
• Phone: 650-232-7200
• Fax: N/A
• Employees: 430
• Year Founded: N/A

Price Target and Rating

• Average Price Target for PROCEPT BioRobotics: $84.13
• High Price Target: $112.00
• Low Price Target: $68.00
• Potential Upside/Downside: +48.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$91.41 million
• Net Margins: -36.20%
• Pretax Margin: -36.20%
• Return on Equity: -28.09%
• Return on Assets: -20.02%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 8.95
• Quick Ratio: 7.75

Sales & Book Value

• Annual Sales: $224.50 million
• Price / Sales: 13.96
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.71 per share
• Price / Book: 7.35

Miscellaneous

• Outstanding Shares: 55,330,000
• Free Float: 45,702,000
• Market Cap: $3.13 billion
• Optionable: Optionable
• Beta: 1.07